reason report
strong fairli valu pipelin catalyst path pt
bottom line report earn provid increment
updat compani clinic program jakafi sale modestli
estim consensu manag rais lower
end prior full year guidanc notabl jakafi sale recent
approv graft-versus-host diseas gvhd indic particularli
strong manag suggest expect sale
year follow quarter updat model reflect
rapid adopt jakafi indic explicitli model two
emerg pipelin asset includ revenu topic
jakafi atop dermat vitiligo royalti partner
inhibitor capmatinib see program rel de-
risk probabl success opportun provid
collect per share risk-adjust npv valuat howev
see compani execut goal diversifi revenu
away legaci jakafi franchis also see catalyst path
appear mostli increment larg anticip believ
success base case expect enthusiasm remain
temper potenti competit overhang jakafi backbon
includ approach competit fedratinib gener eros
anticip well perceiv lack signific return
 expenditur rais pt driven
predominantli model explicit valu dermatolog franchis
out-licens capmatinib see share fairli price
level remain mp
modest jakafi revenu beat rapid uptak newli approv
gvhd program report jakafi net product revenu
repres yoy growth modestli beat estim
consensu manag suggest strong
perform jakafi quarter driven myelofibrosi mf
polycythemia vera pv patient demand well encourag
earli launch expand indic gvhd drug
advanc follow approv versu prior off-label usag
manag comment suggest expect jakafi
revenu come gvhd top tier bone marrow
center purchas drug date opinion rapid adopt
encourag gvhd franchis includ itacitinib although
believ peak collect sale jakafi itacitinib remain
world-wide market suggest rapid jakafi uptak like
plateau rel quickli given result incyt
rais lower end guidanc rang jakafi revenu
anticip midpoint impli yoy
net debt total capit
price-to-earnings lt ep growth
net debt total capit calcul use bv
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep
pleas refer page import disclosur price chart analyst certif
iclusig revenu jakavi/olumi royalti mostli line
estim report iclusig net product revenu europ
royalti novarti nv jakavi sale
royalti relat olumi sale
report figur larg in-lin estim consensu
also report mileston contract revenu
quarter relat collabor innov
updat model includ explicit valu topic jakafi
capmatinib royalti rapid jak adopt gvhd pt
follow posit proof-of-concept data topic jakafi cream
vitiligo see initi takeaway note atop dermat
incorpor explicit valu topic jakafi dermatolog
program model assum launch cream
atop dermat ad peak revenu label
expans vitiligo peak revenu ad
larger opportun albeit fragment multipl topic
inject agent versu vitiligo repres larger unmet need
see insid detail probabl success
program includ per share risk-adjust npv
also follow updat capmatinib inhibitor data present
partner novarti guid nda submiss
explicitli model opportun capmatinib set
receiv tier royalti world-wide sale forecast
global assign probabl success
program result per share risk-adjust npv
updat model reflect financi result report
quarter model chang result new pt
pipelin develop timelin remain track includ gvhd
data readout pemigatinib nda submiss phase dataset
jakafi trial steroid refractori
acut gvhd chronic gvhd expect year-end
larg anticip posit view pivot itacitinib data
trial steroid-nav acut gvhd also expect
year-end nda submiss pemigatinib cholangiocarcinoma
expect year-end well present registr
dataset medic meet two phase trial topic jakafi
vitiligo also expect start year-end target enrol
patient trial evalu jakafi cream bid vs vehicl
primari endpoint score week timelin
guidanc provid initi phase vitiligo data
remain market perform see larg
execut goal diversifi revenu believ current
level clinic commerci success mostli bake jakafi
franchis pipelin enthusiasm temper potenti
competit overhang jakafi includ approach competit
fedratinib pdufa gener eros anticip
given expect success lack clariti potenti blockbust
candid pipelin potenti competit pressur
believ share fairli price remain sidelin
rate corp share market perform pt commerci stage
biotechnolog compani develop drug modul pathway involv cell signal
oncolog autoimmun disord compani solid backbon revenu lead
asset jakafi oral inhibitor jak pathway estim worth per share
howev see compani execut goal diversifi revenu see stock
fulli valu favor upcom catalyst potenti competit fedratinib gener
eros anticip promis asset pipelin topic
jakafi gvhd think opportun alreadi reflect share howev
share could repres good invest investor longer term horizon
beyond one year valuat will invest mid-cap biotechnolog compani solid
financi fundament driven grow commerci backbon anticip minim
volatil clinical/regulatori event
model chang includ introduct explicit valu topic ruxolitinib capmatinib
royalti pt follow posit proof-of-concept data topic ruxolitinib cream
vitiligo atop dermat ad explicit valu topic ruxolitinib dermatolog
program model also ad explicit valu out-licens inhibitor
capmatinib also updat model reflect report financi modestli
increas ramp/penetr jak franchis gvhd chang result new
pt driven primarili addit explicit valu topic ruxolitinib capmatinib
ruxolitinib cream could repres import treatment option atop dermat vitiligo
conduct dilig sever medacorp kol treat ad vitiligo base
assess proof-of-concept clinic data believ topic ruxolitinib could
repres import treatment option patient dermatolog disord use
patient wide rang sever advanc patient extens diseas
think drug could use conjunct system therapi
specif atop dermat medacorp kol enthusiast prospect
non-steroid altern high efficaci clean safety/toler practic
prescrib system treatment regeneron op dupix major
moderate-to-sever ad patient specialist indic often prescrib topic
therapi supplement efficaci achiev system therapi although greater
competit ad rel vitiligo multipl topic inject treatment option
physician see need effect non-steroid topic treatment option beyond pfizer
eucrisa view disappoint medacorp kol highlight margin
efficaci eucrisa well burning/sting sensat report patient key
deterr uptak ruxolitinib cream reproduc phase proof-of-concept data without
burning/sting seen eucrisa physician see meaning role product
base feedback medacorp kol review scientif literatur
segment ad model diseas sever assum ad patent mild
moder remain patient sever depend upon sever
diseas assign differ percentag patient seek new topic treatment kol
spoken see role topic ruxolitinib across spectrum diseas
penetr patient greater sever data readout two phase trial
expect model initi commerci gradual uptak result
peak penetr ad patient depend sever assum
initi price per month annual net price increas vari level
complianc sever patient greatest complianc base assumpt
forecast peak sale topic ruxolitinib ad assign
probabl success result risk-adjust npv per share
medacorp kol also enthusiast potenti topic ruxolitinib
treatment vitiligo larg unmet medic need due lack fda approv
pharmacotherapi current topic agent use off-label treatment vitiligo
signific side effect follow posit proof-of-concept topic ruxolitinib data vitiligo
present wcd june see initi take-away note intend initi two phase
trial end patient trial evalu ruxolitinib cream bid
vs vehicl primari endpoint score week
base propos clinic develop plan estim vitiligo program
approxim one year behind ad program assum label expans start
similar ad segment vitiligo model sever base bodi surfac area bsa
impact assum vitiligo patient mild diseas bsa vitiligo
patient moder diseas bsa less vitiligo
patient sever diseas bsa assum price topic ruxolitinib
rel ad per month also model longer treatment duration/great
complianc vitiligo patient model peak uptak topic jakafi
mild moder sever vitiligo patient respect repres revenu
aggreg model topic ruxolitinib peak revenu assign
similar probabl success vitiligo program result risk-adjust npv per
share
current includ ex-u revenu topic ruxolitinib ad vitiligo
model view potenti upsid previous guid independ team
sale rep commerci team medic affair team need us
initi commerci launch given complex dermatolog market asia europ
suggest like need commerci partner asia though remain open
partnership and/or build forc europ current includ ex-u revenu
topic dermatolog franchis model
capmatinib appear effect nsclc patient alter ad valu
royalti partner novarti capmatinib potent select atp competit type ib
inhibitor evalu patient advanc non-smal cell lung cancer
nsclc harbor exon skip mutat account nsclc updat
capmatinib data present show clinic meaning efficaci durat
regardless line therapi well well-toler safeti profil specif capmatinib
show object respons rate orr patient durat month
orr frontlin patient durat month blind independ
central review birc incyt partner novarti guid nda submiss
model approxim address patient front-lin second-lin
biopsi confirm advanc nsclc exon mutat assum moder
growth due increas diagnosi treatment rate assum initi net price
capmatinib annual price increas result peak revenu
us model ex-u revenu us revenu bring world-wide peak
revenu set receiv tier royalti assign
probabl success attribut per share base anticip royalti
use risk-adjust sum-of-the-part methodolog valu examin clinic
regulatori commerci risk opportun individu indic region
assign probabl success account likelihood achiev
revenues/expens risk-adjust sum-of-the-part analysi appli discount rate
cash flow gener asset determin total net present valu
risk-adjust asset total npv reflect remain clinic regulatori risk
productpeak revenu mn phase developmentnpv mn probabl successrisk-adjust npv mn expect launchnet current value/sharejakafi polycythemia eu us ra eu ra ad indic inhibit fgfr fl mcl cmet ww jak atop jak oncolog pipelinei ii asset share count total risk-adjust equiti valu risk residu non-deplet profitabilityincyt corpor mf/pvolumianticlusigjak jakearli oncolog pipelin corpor
commerci risk competit compani develop treatment myelofibrosi
polycythemia vera therapeut area compet repres risk
clinic risk clinic trial failur incyt compound develop includ itacitinib
pemigatinib ruxolitinib compani earli stage pipelin repres risk
current valuat
regulatori risk even posit clinic data regulatori approv need market
prescript drug develop market regul may declin approv applic
incyt development-stag compound repres risk current valuat
 mn except ep
product revenu
chang fair valu acquisition-rel conting consider
earn tax ebt
balanc sheet mn
compani report svb leerink estim
